Novel, oral GLP-1 receptor agonist significantly reduced HbA1c and weight in type 2 diabetes patients: Phase IIa trial
USA: Findings from a phase IIa trial revealed a significant reduction in weight and HbA1c (-3.26% and -1.02% placebo-adjusted change with 90 mg, respectively) after 12 weeks with a novel, oral GLP-1 receptor agonist in patients with type 2 diabetes. A clinical-stage global biopharmaceutical company Structure Therapeutics Inc. provided a comprehensive development program update for […]